State-of-the-art facilities
Oxford, UK
Viral vector manufacturing in Oxford, UK
Our facilities in Oxford offer 94,000 square feet of space for specialised cell and gene therapy manufacturing, along with a further 20,000 square feet available for flexible expansion.
Benefit from:
6 GMP manufacturing suites
Next generation single-use 200L and 1,000L bioreactors
2 Fill Finish suites
Warehouse and cold chain facilities
Boston, US
Viral vector manufacturing in Boston, US
Our facility near Boston offers 91,000 square feet of manufacturing space, covering full scope process development and GMP operations for Adeno-Associated Viruses (AAV) and Lentivirus.
Benefit from:
3 x 500L bioreactors
Our proprietary serum-free suspension process for early-stage clinical manufacturing
Our proprietary AAV platform
Proven scalability to 2,000L
Lyon and Strasbourg, France
Viral vector manufacturing in France
Our facilities in France offer 6500 square meters in Lyon and 4900 square meters in Strasbourg of space for specialised cell and gene therapy manufacturing.
Benefit from:
2 fill/finish lines
Up to 10,000 vials per batch
Benefit from our deep scientific understanding
Working with Oxford Biomedica gives you access to capabilities that go far beyond conventional contract manufacturing services for viral vectors. Our commercial experience, scientific understanding, and development expertise complement our state of the art manufacturing facilities. Our teams are passionate about helping you get the results you want.
Benefit from our rigorous controls
When you use an Oxford Biomedica platform, you get a comprehensive, end-to-end CMC service. You can be sure our quality-focused GMP manufacturing processes will support your viral vector product through every step of development through to commercialisation, all supported by robust and compliant analytics.